Heterogeneous Or Solid Phase Assay System (e.g., Elisa, Etc.) Patents (Class 435/7.92)
  • Patent number: 10267802
    Abstract: Cellular markers indicating a poor prognosis for ovarian cancer patients are disclosed. In particular, the invention relates to methods utilizing the frequency of a subset of cells in ovarian tumor tissue expressing vimentin, cMyc, or HE4, or any combination thereof, to predict an ovarian cancer patient will relapse.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 23, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jonathan Berek, Wendy Fantl, Veronica Gonzalez, Garry P. Nolan, Nikolay Samusik
  • Patent number: 10254279
    Abstract: A system and method includes a test container for detecting a target substance in a consumable sample, where the test container includes a test container body defining a test container top, a test container bottom opposing the test container top, a first chamber proximal the test container top, and a second chamber proximal the test container bottom, a magnetic diaphragm situated between the first chamber and the second chamber, the magnetic diaphragm obstructing flow of the consumable sample, and the magnetic diaphragm including a magnetic element embedded in the magnetic diaphragm, and a driving element geometrically complementary to the first chamber, the driving element including a consumable sample grinding feature protruding from a surface of the driving element.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 9, 2019
    Assignee: Nima Labs, Inc.
    Inventors: Scott Sundvor, Steven Portela, Jonathan Ward, John Walton, Jonathan William Kiel, Jeffrey Mekler, Shireen Yates, Jacob Mooney, Dane Weitmann, Joseph Horrell
  • Patent number: 10234462
    Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10222375
    Abstract: The machine is configured to perform an automated rapid plasma reagent (RPR) agglutination test or other agglutination test. The machine includes a sample rack with multiple sample locations thereon and a reagent rack for storing of reagent. A shaker assembly supports at least one microtiter plate or other well supporting structure thereon with a plurality of wells in the plate. An automated pipette accesses samples and reagent and deposits them within wells of the microtiter plate. The shaker assembly shakes multiple samples within the wells of the microtiter plate. Finally, a camera photographs the wells of the plate, preferably from above with a light source below and the plate at least partially transparent. The image is then analyzed in an automated fashion to determine whether a ring of contrast material has remained smooth indicative of a non-reactive sample or has agglutinated/clumped together indicative of a reactive sample.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 5, 2019
    Assignee: Gold Standard Diagnostics
    Inventors: Peter Van Praet, Jennifer Roth, John Griffiths
  • Patent number: 10213459
    Abstract: Mitochondrial compositions and therapeutic methods of using same. Compositions of partially purified functional mitochondria and methods of using the compositions to treat conditions which benefit from increased mitochondrial function by administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 26, 2019
    Inventors: Natalie Yivgi-Ohana, Uriel Halavee
  • Patent number: 10202635
    Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
  • Patent number: 10195580
    Abstract: A method of creating a mask on a surface of a substrate is disclosed. The substrate comprises a plurality of spaced heating elements on or proximal to the surface. The method comprises applying a layer of masking material to the surface and employing the heating elements to apply energy to a phase change in the masking material at the selected sites such that it adheres to the surface or can be displaced from the surface to mask or unmask the selected sites respectively. A method of synthesising an array of molecules, an apparatus for selectively masking one or more sites on a surface and a semi-conductor chip that uses micro-heaters to modulate a masking layer on areas of the chip surface.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: February 5, 2019
    Assignee: EVONETIX LTD.
    Inventors: Daniel Arthur Hall, Christopher John Favero Jordan
  • Patent number: 10174370
    Abstract: The present invention relates to a non-destructive method for analyzing maternal DNA of a seed. In this method the DNA may be dislodged from the seed coat surface and may be used to collect information on the genome of the maternal parent of the seed. Also, the present invention provides a high throughput DNA analysis system for large plant populations.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 8, 2019
    Inventor: Cornelis Maria Petrus Van Dun
  • Patent number: 10175258
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: January 8, 2019
    Inventors: Stephen Peter Fitzgerald, Paul John Innocenzi, Ivan Robert McConnell, Philip Andrew Lowry, Elouard Benchikh
  • Patent number: 10175250
    Abstract: The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. Diagnosis and prognosis is conducted by determining the amount of nitrated cardiac troponin I in serum samples of subjects and the ratio of nitrated cardiac troponin I to non-nitrated cardiac troponin I in serum samples of subjects. This biomarker can be detected by immunoassay techniques and tandem mass spectrometry. The present invention further relates to peptides, antibodies, compositions, methods, techniques, tests and kits for the identification and quantification of nitrated cardiac troponin I in samples of subjects.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: January 8, 2019
    Inventors: Gabriela Venturini Da Silva, Alexandre Da Costa Pereira, José Eduardo Krieger, Deborah Schechtman, Pedro Lemos, Jeane Mike Tsutsui, Valdemir Melechco Carvalho, Karina Helena Morais Cardozo
  • Patent number: 10126309
    Abstract: The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 13, 2018
    Inventor: John E. Wiktorowicz
  • Patent number: 10107822
    Abstract: Methods, kits, and diagnostic devices are disclosed for diagnosing an invasive fungal infection in a subject by measuring a T-cell interferon gamma (IFN-?) response after exposure to a fungal antigen.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: October 23, 2018
    Assignee: The Johns Hopkins University
    Inventor: Kieren Marr
  • Patent number: 10101327
    Abstract: A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (ACYF) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 16, 2018
    Assignee: Cornell University
    Inventor: Bettina Wagner
  • Patent number: 10101340
    Abstract: Described is a method of detecting a protein fragment in a urine sample and a serum sample. The protein fragment is a urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, or serum osteopontin fragment. The urine sample and the serum sample are obtained from the same individual.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: October 16, 2018
    Assignee: Bio Preventive Medicine Corp.
    Inventors: Wei-Ya Lin, Mary Ya-Ping Yeh, Tzu-Ling Tseng, Ping-Fu Cheng, Tsai-Wei Hsu, Hung-Yi Li, Yi-Ting Chen, Yuh-Feng Ling, Jin-Shuen Chen, Yen-Peng Li
  • Patent number: 10101319
    Abstract: The present invention relates to a method of identifying a subject with a Plasmodium infection. The present invention also relates to a method for monitoring a subject with a Plasmodium infection, for example, following treatment with an anti-malaria compound. Also provided are methods of identifying a compound to treat a Plasmodium infection.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: October 16, 2018
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Stephen Trowell, Amalia Berna, Benjamin Padovan, Vicki Locke
  • Patent number: 10067125
    Abstract: The invention relates to methods of reliably and quantitatively determining the amount of an analyte of interest in a fluid sample using a flow-induced assay, such as an immunochromatographic assay, in which spatiotemporal measurements are recorded during the course of the assay reaction, generating a spatiotemporal dataset, and subsequently analyzed. The invention also relates to a system incorporating instruments for recording spatiotemporal datasets (spatiotemporal data recorders), devices comprised of flow-induced assays configured for analysis on a spatiotemporal recorder, and programs for analyzing the recorded spatiotemporal datasets.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: September 4, 2018
    Inventor: Edward L Mamenta
  • Patent number: 10067127
    Abstract: An object of the present invention is to provide a method of detecting an analyte (antigen) in a sample by an antigen-antibody reaction with an antibody fragment including an antigen binding region for the analyte antigen (hereinafter “an antibody fragment comprising an antigen binding region for an analyte antigen” will simply be referred to as “an antibody fragment against antigen”), the method suppressing nonspecific reaction that is caused by antibody fragments. More specifically, provided is a method of detecting an analyte antigen in a sample by an antigen-antibody reaction with an antibody fragment against antigen, the method comprising the steps of: a) bringing a sample into contact with a denatured antibody fragment; and b) bringing the sample into contact with the antibody fragment immobilized on an insoluble carrier after the step of a), the method suppressing nonspecific reaction.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: September 4, 2018
    Inventors: Chie Kataoka, Hiroshi Takahashi, Tadaaki Yoshida, Yoshimasa Banba
  • Patent number: 10067143
    Abstract: The present application relates to a method of assaying ubiquitination in a sample by combining ubiquitin together with a substrate in a sample containing UBE1, UbcH3, Skp2-isoform 1, Skp1, Cull, Rbx1, Cks1, CDK2 and Cyclin E1 under conditions suitable for ubiquitination to take place, exposing the sample to a labelled binding partner which is specific for the ubiquitin, and measuring the amount of ubiquitin bound to the substrate.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 4, 2018
    Assignee: ITI Scotland Limited
    Inventor: Jonathan Peter Clark
  • Patent number: 10040866
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 7, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
  • Patent number: 10041962
    Abstract: A sensing paper suitable for sensing a target substance is provided. The sensing paper includes a filter paper, a wax, and a plurality of fluorescent materials. The wax is printed on the filter paper, wherein the sensing paper has a plurality of opening patterns, and each of the opening patterns respectively exposes a portion of the filter paper. The plurality of fluorescent materials is attached to the portion of the filter paper that is exposed by each of the opening patterns. Each of the fluorescent materials emits fluorescence, and after the fluorescent materials react with the target substance, an intensity of the fluorescence emitted by the fluorescent materials is quenched.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: August 7, 2018
    Assignee: National Taiwan University
    Inventors: Huan-Tsung Chang, Yao-Te Yen, Yu-Syuan Lin
  • Patent number: 10028955
    Abstract: The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 24, 2018
    Assignee: Novartis AG
    Inventors: Michaela Kneissel, Vito Guagnano, Diana Graus Porta, Simon Wöhrle
  • Patent number: 10023609
    Abstract: A method of reducing aggregate content in a preparation having a target protein includes contacting the preparation with an alkyl cation to form a mixture, and contacting the mixture with at least one functionalized solid to remove excess alkyl cation.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 17, 2018
    Inventor: Peter Stanley Gagnon
  • Patent number: 10001491
    Abstract: The present invention relates to a method for the in vitro determination of the radiosensitivity of a subject. More particularly, the invention relates to a method comprising a step of inducing an exogenous stress on a biological sample from a subject, followed by the comparison of the presence or level of at least one compound chosen in a group of defined compounds, in said biological sample and in a reference sample. The present invention also relates to the use of said at least one compound as predictive biomarker of the radio-sensitivity of a subject. The invention also relates to a kit for the detection of the presence or level of at least one of said compounds, usable in a method according to the invention.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 19, 2018
    Assignees: Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: David Azria, Jerome Lacombe, Jerome Solassol, Alain Mange
  • Patent number: 9989523
    Abstract: The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 5, 2018
    Assignee: LEUKODX LTD.
    Inventors: Harvey Lee Kasdan, Julien Meissonnier, Yoav Zuta, Bruce Davis, Micha Rosen, Yael Himmel, Yehoshua Broder
  • Patent number: 9970943
    Abstract: Methods for interpretation of mass spectrometric tests for clinical biomarkers in which the amounts of internal standards are set to equal clinical evaluation thresholds, and preparations for adding stable isotope labeled peptide species to sample digests while minimizing losses and alterations in peptide stoichiometry.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: May 15, 2018
    Assignee: Anderson Forschung Group, LLC
    Inventor: N. Leigh Anderson
  • Patent number: 9969791
    Abstract: The present invention provides isolated polypeptides comprising a modified fibronectin fragment that comprises FNIII 10 and optionally further comprising FNIII 9. Also provided are pharmaceutical compositions comprising the polypeptides and methods of making and using the polypeptides.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 15, 2018
    Inventors: Woei-Jer Chuang, Yung-Sheng Chang
  • Patent number: 9970929
    Abstract: Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: May 15, 2018
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
  • Patent number: 9968903
    Abstract: The invention features methods of making devices, or “platens”, having a high-density array of through-holes, as well as methods of cleaning and refurbishing the surfaces of the platens. The invention further features methods of making high-density arrays of chemical, biochemical, and biological compounds, having many advantages over conventional, lower-density arrays. The invention includes methods by which many physical, chemical or biological transformations can be implemented in serial or in parallel within each addressable through-hole of the devices. Additionally, the invention includes methods of analyzing the contents of the array, including assaying of physical properties of the samples.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 15, 2018
    Assignee: Life Technologies Corporation
    Inventors: Robert Hess, John Linton, Tanya S. Kanigan, Colin Brenan, Can Ozbal
  • Patent number: 9958449
    Abstract: The present invention relates to methods and compounds for enzyme-mediated amplification of target-associated signals for visualization of biological or chemical targets in samples, wherein the targets are immobilized, in particular the invention relates to the oxidoreductase-mediated signal amplification for visualization of targets in samples comprising cells. The methods of the invention are particular useful for qualitative and quantitative evaluation of biological markers relating to medical diagnostic and therapy.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 1, 2018
    Assignee: DAKO DENMARK A/S
    Inventors: Jesper Lohse, Galina Skladchikova
  • Patent number: 9952206
    Abstract: The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: April 24, 2018
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Patent number: 9945871
    Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: April 17, 2018
    Inventors: Laurent Martinez, Bertrand Perret, Annelise Genoux
  • Patent number: 9939432
    Abstract: A system and method for detecting harmful substances within a consumable sample comprising: receiving a consumable sample at a first chamber of a test container; transforming the consumable sample into a homogenized sample upon processing of the consumable sample; delivering the homogenized sample to a second chamber of the test container, wherein the second chamber is configured to receive the homogenized sample comprises an outlet port; mixing the homogenized sample with a process reagent within the second chamber, thereby producing a dispersion; transmitting a volume of the dispersion to an analysis chamber, of the test container, configured to position a detection substrate proximal the port of the second chamber and comprising a detection window that enables detection of presence of the allergen; and detecting presence of the allergen within the consumable sample by way of an optical sensor configured to detect signals indicative of the allergen through the detection window.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: April 10, 2018
    Assignee: Nima Labs, Inc.
    Inventors: Scott Sundvor, Steven Portela, Jonathan Ward, John Walton, Jonathan William Kiel, Jeffrey Mekler, Shireen Yates, Jacob Mooney
  • Patent number: 9926364
    Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: March 27, 2018
    Assignee: ARGEN-X N.V.
    Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier
  • Patent number: 9925509
    Abstract: The present invention relates to a method for combinatorial particle manipulation for producing high-density molecule arrays, and to the high-density molecule arrays obtained therefrom. In particular, the present invention relates to a method for producing high-density molecule arrays, in particular peptide or oligonucleotide arrays, by combinatorial patterning of particles, wherein the patterning is achieved by the selective and direct action of electromagnetic radiation.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: March 27, 2018
    Assignee: PEPperPRINTGmbH (DE/DE)
    Inventors: Frieder Märkle, Alexander Nesterov-Müller, Frank Breitling, Felix Löffler, Sebastian Schillo, Valentina Bykovskaya, Clemens Von Bojnicic-Kninski, Klaus Leibe
  • Patent number: 9910049
    Abstract: Methods and kits are provided for amplifying and detecting A? proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A? protein may include contacting the sample with a monomeric, folded A? protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A? protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A? protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A? aggregate present; and determining the presence of the soluble, misfolded A? protein in the sample by detecting at least a portion of the amplified portion of misfolded A? protein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 6, 2018
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Patent number: 9902755
    Abstract: A Treponema pallidum triplet antigen construct is disclosed which includes three Treponema pallidum antigens (TP15, TP17, and TP47), as well as a ten amino acid leader sequence (tag 261) and human copper zinc superoxide dismutase (hSOD). This construct is optimized for in vitro diagnosis of syphilis infection. Plasmids containing DNA encoding the triplet antigen, host cells, production methods, detection methods, and kits are also disclosed.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: February 27, 2018
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Jian Zheng, Renee Yura, Jianping Yang
  • Patent number: 9903875
    Abstract: The invention is to devices and method for rapid determination of analytes in liquid samples by various assays including immunoassays incorporating a sample dilution feature for forming a diluted sample for analysis. The devices and methods also include a dilution verification feature for verifying the degree of dilution of the diluted sample. The devices preferably are capable of being used in the point-of-care diagnostic field is provided.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: February 27, 2018
    Assignee: Abbott Point of Care Inc.
    Inventors: Cary James Miller, Graham Davis, Michael Zelin
  • Patent number: 9873871
    Abstract: The invention is a methodology which makes it possible to select from a very large number of cells, a single cell or cells of interest and obtain specific information from those cells in a rapid and efficient manner. As an example of the methodology, a large number of antibody producing cells such as plasma cells are separated so that these individual antibody producing plasma cells are placed in individual wells. The cells are allowed to produce antibodies and the antibodies in the wells are then contacted with a protein bound to a solid surface such as a well top. The protein universally and specifically binds antibodies in the wells. The surface or well tray top includes addresses configured such that each address is specifically related to one of the individual wells containing a cell producing antibodies.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: January 23, 2018
    Inventors: Chun-Nan Chen, James O. Bowlby, Richard Aleck Jorgensen, Mark Jay Shlomchik
  • Patent number: 9873739
    Abstract: The disclosure relates to compositions and methods of mitigating tissue damage and fibrosis in a patient by modulating latent transforming growth factor beta binding protein (LTBP4)-induced proteolysis of a Transforming Growth Factor-beta (TGF?) superfamily protein.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: January 23, 2018
    Assignee: Ikaika Therapeutics, LLC
    Inventors: Elizabeth McNally, Ahlke Heydemann, Ermelinda Ceco
  • Patent number: 9862773
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD9 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome isolation kits using the antibody.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 9, 2018
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Patent number: 9862762
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 9, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
  • Patent number: 9856296
    Abstract: The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: January 2, 2018
    Assignee: DESENTUM OY
    Inventors: Kristiina Takkinen, Marja-Leena Laukkanen, Hans Söderlund, Sirpa Jylhä, Heidi Holkeri, Merja Niemi, Janne Jänis, Juha Rouvinen
  • Patent number: 9857380
    Abstract: The present invention makes use of immunoassays, such as sandwich ELISAs, to profile the circulating concentration of elastic fiber and microfibril fragments in samples from individuals with diseases associated with elastic fiber and/or microfibril degradation. Examples of such diseases include, Marfan's syndrome, aortic aneurysm, and scleroderma. Profiling the concentration of such fragments can be used to diagnose disease and monitor disease progression.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 2, 2018
    Inventors: Lynn Y. Sakai, Lynn M. Marshall, Eric J. Carlson, Noe L. Charbonneau, Susan J. Hayflick
  • Patent number: 9851352
    Abstract: The invention provides methods, kits, compositions, and devices useful for detection of antibodies that bind to Ehrlichia antigens and/or for differentiation of certain Ehrlichia species from others. In particular, the invention provides methods and kits useful for identifying species of Ehrlichia using populations of isolated peptides.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: December 26, 2017
    Assignee: ABAXIS, INC.
    Inventors: Rajesh K. Mehra, Jeremy D. Walker, Kenneth P. Aron, Dennis M. Bleile, Cristina R. Cuesico, Timothy P. Forsyth
  • Patent number: 9841430
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind to human fractional C-Reactive Protein (fracCRP), kits containing these antibodies and antibody fragments, and assays using these antibodies and antibody fragments.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: December 12, 2017
    Assignee: University of Massachusettes
    Inventor: Charles R. Kiefer
  • Patent number: 9790269
    Abstract: The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and/or treatment of amyloid diseases or symptoms thereof.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: October 17, 2017
    Inventors: Xin Jiang, Jeffery W. Kelly, Justin Chapman
  • Patent number: 9768817
    Abstract: A cell phone case including an additive for providing desired properties of the cell phone case. The additive can be a fragrance for improving a scent of the cell phone case. The additive can also include a antimicrobial agent to create an antimicrobial device effective in reducing or eliminating bacteria on a surface of the cell phone case.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: September 19, 2017
    Inventor: Al Santelli
  • Patent number: 9758840
    Abstract: The present invention provides systems, methods, and compositions for identifying a subject as infected with a parasite by detecting nucleic acid from an endosymbiont of the parasite in a sample from the subject. In certain embodiments, the parasite is a nematode that infects humans or dogs (e.g., D. immitis, O. volvulus, W. bancrofti, B. timori, or B. malayi) and the endosymbiont is Wolbachia.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 12, 2017
    Inventors: Mark W. Eshoo, Christopher Crowder
  • Patent number: 9745573
    Abstract: The present invention is directed to methods and compositions for generating a pool of oligonucleotides. The invention finds use in preparing a population or subpopulations of oligonucleotides in solution. The pool of oligonucleotides finds use in a variety of nucleic acid detection and/or amplification assays.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 29, 2017
    Assignee: Illumina, Inc.
    Inventors: John R. Stuelpnagel, Mark Chee
  • Patent number: 9732153
    Abstract: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 15, 2017
    Inventors: Lior Carmon, Riva Kovjazin